NCT03195452View on ClinicalTrials.gov

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

October 30, 2019

Study Completion Date

May 6, 2020

Conditions
Virus-HIV
Interventions
DRUG

Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)

All virologically suppressed

Trial Locations (17)

Unknown

CHU De Bordeaux, Bordeaux

CH de la Roche Sur Yon, La Roche-sur-Yon

CH du Mans, Le Mans

CHU de Lyon, Lyon

CHRU de Montpellier, Montpellier

CHU of NANTES, Nantes

CHU de Nice, Nice

CHR orléans, Orléans

CHU de Bichat, Paris

CHu hotel dieu, Paris

CHU la pitié, Paris

Hopital Avicenne, Paris

Hopital Necker, Paris

Hopital St Louis, Paris

CHU de Reims, Reims

CH de Tourcoing, Tourcoing

CHRU de Tours, Tours

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT03195452 - QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient | Biotech Hunter | Biotech Hunter